Allergan PLC finally gave in to activist investor Appaloosa LP's demand that the pharma's CEO and chairman roles be separated, but the decision to give those roles to two different people won't go into effect until current CEO and Chairman Brent Saunders leaves the company.
Allergan Acquiesces To Activist Appaloosa With CEO-Chairman Role Split, But Not Yet
Allergan will split the CEO and chairman roles as requested by Appaloosa, but only in the next leadership transition. The activist shareholder fired back with renewed opposition to leaving Brent Saunders in both top jobs.

More from Leadership
More from Scrip
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.